▲Pfizer has started a clinical trial for an oral treatment for COVID-19.
Pfizer, a US pharmaceutical company, is entering a clinical trial for an oral treatment for the novel coronavirus infection (COVID-19). As the spread of COVID-19 continues, attention is paid to whether oral treatments will become the second ‘game changer’ after vaccines.
Pfizer announced its second quarter earnings report on the 28th (local time), saying, “We have begun phase 2 and 3 trials on patients this month,” and predicted that “the results will come out in the fourth quarter.”
Existing treatments for COVID-19 must be administered in the form of injections at the hospital. Currently on the market, there are ‘Remdesivir’ from Gilead Sciences in the US, which has received FDA approval, and ‘Rekkorna’ from Celltrion, which has been approved in Korea. Since these formulations are for intravenous injection, they are evaluated to have limitations in their widespread use.
If oral COVID-19 treatment is commercialized, accessibility will increase. There is also a prospect that it will be a game-changer for the end of Corona 19 as it can be treated by taking pills like taking cold medicine at home if it is not severe. Like the flu antiviral drugs ‘Tamiflu’ and ‘Xofluza’, Corona 19 patients can quickly cope with them at home by taking medicine.
Currently, global pharmaceutical companies that are developing oral treatments for COVID-19 are MSD (Merck), Roche, Pfizer, and Shionogi (Japanese pharmaceutical company). In Korea, Daewoong Pharm, Bukwang Pharm, and Shinpoong Pharm.
In addition, Pfizer announced that it has started a phase 3 clinical trial for the vaccine booster shot. Pfizer said, “As a result of analyzing the data available so far, if at least 6 months have passed after the second dose and the booster shot is given, the concentration of neutralizing antibody against the delta mutation is 5 times (younger people) or 11 times ( It was higher than the elderly),” he said.
Meanwhile, Pfizer raised its COVID-19 vaccine sales forecast for this year by 28.8% from $26 billion (about 30.4 trillion won) to $33.5 billion (about 386 trillion won). Pfizer explained, “Based on the contract status by mid-July, this reflects the fact that it is expected to supply 2.1 billion doses of vaccine this year.”
Pfizer’s overall sales forecast for this year is between $78 billion and $80 billion (about 9012 trillion won to 92.3 trillion won), compared to $70.5 billion to 72.5 billion won (about 8135 trillion won to 83.66 trillion won). raised about a billion dollars more.